Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

BeOne Medicines Ltd. - American Depositary Shares (NQ:ONC)

316.33 +1.26 (+0.40%)

Streaming Delayed Price Updated: 2:56 PM EDT, May 13, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	127,571
Open	310.72
Bid (Size)	315.80 (40)
Ask (Size)	316.99 (160)
Prev. Close	315.07
Today's Range	307.21 - 322.45
52wk Range	218.31 - 385.22
Shares Outstanding	1,211,067,023
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

BeOne Medicines’ BEQALZI™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma

Today 13:27 EDT

From BeOne Medicines Ltd.

Via Business Wire

BeOne Medicines Announces First Quarter 2026 Financial Results and Business Updates

May 06, 2026

From BeOne Medicines Ltd

Via Business Wire

Performance

YTD	+1.7%	+1.7%
1 Month	+3.5%	+3.5%
3 Month	-10.5%	-10.5%
6 Month	-7.9%	-7.9%
1 Year	+35.6%	+35.6%

More News

U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA

April 29, 2026

From BeOne Medicines Ltd.

Via Business Wire

BEONE MEDICINES LTD-ADR (NASDAQ:ONC) Passes Minervini's SEPA Screen with Strong Technicals and High Growth Momentum ↗

February 26, 2026

Via Chartmill

BEONE MEDICINES LTD-ADR (NASDAQ:ONC) Passes Minervini Trend Template and Strong Growth Scan ↗

January 21, 2026

Via Chartmill

BeOne Medicines to Announce First Quarter 2026 Financial Results on May 6

April 22, 2026

From BeOne Medicines Ltd.

Via Business Wire

This Fintech Stock Is Up 21% in a Year as Profits Surge, but One Fund's Nearly $300 Million Sale Cut Its Stake in Half ↗

March 19, 2026

Via The Motley Fool

BeOne Medicines Announces Fourth Quarter and Full Year 2025 Financial Results, Highlighting Global Success of BRUKINSA and Foundational Oncology Leadership

February 26, 2026

From BeOne Medicines Ltd.

Via Business Wire

Investor Buys Up $81 Million in Praxis Stock as Shares Soar Over 300% in One Year ↗

February 23, 2026

Via The Motley Fool

This Fund Bet Nearly $40 Million on GRAIL Last Quarter. The Stock Just Plunged Over 50% ↗

February 23, 2026

Via The Motley Fool

3 Brilliant Growth Stocks to Buy Now and Hold for the Long Term ↗

February 21, 2026

Via The Motley Fool

HHLR Advisors Fully Exits Baidu as AI Push Tests Its Advertising-Funded Model ↗

February 20, 2026

Via The Motley Fool

BeOne Medicines to Present at Upcoming Investor Conferences

February 17, 2026

From BeOne Medicines Ltd.

Via Business Wire

Prediction: These 3 Stocks Will Crush the Market in 2026 ↗

February 16, 2026

Via The Motley Fool

BeOne Medicines to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26

February 11, 2026

From BeOne Medicines Ltd.

Via Business Wire

3 Stocks to Buy in February ↗

February 02, 2026

Via The Motley Fool

BeOne Medicines Highlights Global Oncology Leadership at 44th Annual J.P. Morgan Healthcare Conference

January 13, 2026

From BeOne Medicines Ltd.

Via Business Wire

ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA

January 06, 2026

From BeOne Medicines Ltd.

Via Business Wire

BeOne Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference

December 23, 2025

From BeOne Medicines Ltd.

Via Business Wire

BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma

December 18, 2025

From BeOne Medicines Ltd.

Via Business Wire

BRUKINSA Delivers Landmark 74% 6-Year PFS in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia

December 08, 2025

From BeOne Medicines Ltd.

Via Business Wire

BeOne Medicines Announced Sonrotoclax In Combination With BRUKINSA Demonstrated Rapid MRD Negativity In Treatment-naive CLL, Regardless Of High-risk Features ↗

December 07, 2025

Via Benzinga

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies

December 07, 2025

From BeOne Medicines Ltd.

Via Business Wire

Medicare Slashes Ozempic's Price Tag 71%; Why Novo Nordisk Rallied ↗

November 26, 2025

Via Investor's Business Daily

U.S. FDA Grants Priority Review to Sonrotoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

November 26, 2025

From BeOne Medicines Ltd.

Via Business Wire

Frequently Asked Questions

Is BeOne Medicines Ltd. - American Depositary Shares publicly traded?

Yes, BeOne Medicines Ltd. - American Depositary Shares is publicly traded.

What exchange does BeOne Medicines Ltd. - American Depositary Shares trade on?

BeOne Medicines Ltd. - American Depositary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for BeOne Medicines Ltd. - American Depositary Shares?

The ticker symbol for BeOne Medicines Ltd. - American Depositary Shares is ONC on the Nasdaq Stock Market

What is the current price of BeOne Medicines Ltd. - American Depositary Shares?

The current price of BeOne Medicines Ltd. - American Depositary Shares is 316.33

When was BeOne Medicines Ltd. - American Depositary Shares last traded?

The last trade of BeOne Medicines Ltd. - American Depositary Shares was at 05/13/26 02:56 PM ET

What is the market capitalization of BeOne Medicines Ltd. - American Depositary Shares?

The market capitalization of BeOne Medicines Ltd. - American Depositary Shares is 383.10B

How many shares of BeOne Medicines Ltd. - American Depositary Shares are outstanding?

BeOne Medicines Ltd. - American Depositary Shares has 383B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.